Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Current
    • Residents & Fellows
    • Without Borders
    • Practice Buzz
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Current
    • Residents & Fellows
    • Without Borders
    • Practice Buzz
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub

Share

October 2016; 3 (5) EditorialOpen Access

Targeting “bad” B cells in multiple sclerosis

Could laquinimod be part of the armamentarium?

Thomas G. Forsthuber, Olaf Stuve
First published September 21, 2016, DOI: https://doi.org/10.1212/NXI.0000000000000283
Thomas G. Forsthuber
From the Department of Biology (T.G.F.), University of Texas at San Antonio; Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service, Dallas.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olaf Stuve
From the Department of Biology (T.G.F.), University of Texas at San Antonio; Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service, Dallas.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Targeting “bad” B cells in multiple sclerosis
Could laquinimod be part of the armamentarium?
Thomas G. Forsthuber, Olaf Stuve
Neurol Neuroimmunol Neuroinflamm Oct 2016, 3 (5) e283; DOI: 10.1212/NXI.0000000000000283

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
580

Share

  • Article
  • Info & Disclosures
Loading

Laquinimod is an orally available quinoline 3-carboxamide derivative drug studied in phase II and III clinical trials for relapsing-remitting multiple sclerosis (RRMS), systemic lupus erythematosus, and Crohn disease. Laquinimod has shown promise in RRMS clinical trials,1,2 and identifying the mechanism underlying its disease-modifying effects could help target it to the patient population where it would be most effective. Studies in experimental autoimmune encephalomyelitis (EAE) models of multiple sclerosis (MS) have suggested that the drug may ameliorate disease by modulating innate and adaptive immune responses, for example via effects on macrophages/monocytes, dendritic cells (DCs), and T-helper (Th) cells.3,–,5 However, its key effector mechanisms and the cellular targets by which the drug ameliorates disease are still not fully resolved. The article by Varrin-Doyer et al.6 in this issue of Neurology® Neuroimmunology & Neuroinflammation sheds new light on this question and provides important insights that could be relevant for the treatment of MS. In elegant experiments, Varrin-Doyer et al. provide convincing evidence that treatment with laquinimod strongly ameliorates disease in 2 models of recombinant myelin oligodendrocyte glycoprotein (MOG)–induced EAE and spontaneous EAE in mice transgenic for a T-cell receptor specific for MOG35-55 peptide and a MOG-specific immunoglobulin H chain knock-in (2D2 × Th mice). In both of these models, the authors show that laquinimod treatment prevented the development of T-follicular-helper (Tfh) cells and decreased the production of MOG-specific immunoglobulin G antibodies. Interestingly, in a spontaneous model of EAE, associated with the formation of meningeal follicle-like structures that are populated by B and T cells,7 laquinimod therapy reduced the number and the size of these cellular aggregates.

It is important to note that disease induced by recombinant MOG in this model is critically dependent on B cells and myelin antigen uptake via the B-cell receptor and presentation to autoimmune CD4+ T cells. In contrast, simultaneous expression of a MOG-specific T-cell receptor and MOG-specific immunoglobulin H chain in the 2D2 × Th mice leads to spontaneous disease replicating human neuromyelitis optica (NMO), and MOG-specific autoantibodies are pathognomonic in this condition. Thus, the results by Varrin-Doyer et al. show the efficacy of laquinimod in B-cell-driven EAE disease models with CNS pathology induced by different pathogenic effector mechanisms.

The question to be asked then is how relevant is this observation for MS? B cells, one should recall, have moved in and out of the center of attention in the etiology of MS since the discovery of oligoclonal bands in the CSF of patients with MS in the 1940s. Obviously, a key role of B cells is the production of antibodies, and, consequently, detection of autoantibodies for diagnostic and prognostic purposes in patients with MS has been researched for many years. More recently, other functions of B cells have attracted attention that could account for their potential role in the etiology and pathogenesis of MS, which center on their antigen presentation and T-cell-activating properties, regulatory function (i.e., interleukin-10-producing regulatory B cells), and the enigmatic role of meningeal B-cell follicles. The rapid clinical improvement observed after B-cell depletion with rituximab8 and ocrelizumab9 in patients with MS supports the concept that B-cell functions besides antibody production may be important for modulating disease in RRMS, in particular since anti-CD20 therapy does not deplete long-living antibody-producing plasma cells, and therefore should have less of an immediate effect on potentially pathogenic autoantibodies. In contrast, the pathogenic role of autoantibodies in NMO is better established and supported by animal studies, such as spontaneous disease development in 2D2 × Th transgenic mice.7

While the net effect of laquinimod in this study resulted in the impairment of the B-cell effector responses in the tested disease models, the logical next question is if this was due to direct effects of the drug on B cells, or whether this was indirectly achieved by modulating other cells. Along these lines, laquinimod inhibited the development of Tfh cells, conceivably by modulating the function of follicular DCs. Induction of regulatory T cells may have contributed to the Tfh defect. Evidence for a direct effect of laquinimod on B cells comes from in vitro studies with human B cells,10 and the study by Varrin-Doyer et al. adds to this view by showing that laquinimod-treated B cells were impaired in their ability to induce Tfh cells upon adoptive transfer to B-cell-deficient mice. This effect did not seem to be the result of impaired antigen presentation, but conceivably, downregulation of CD40 on laquinimod treated B cells could point to a mechanism.

As stated above, a potentially important finding was the decrease in meningeal B-cell aggregates noticed in EAE mice treated with laquinimod. Meningeal B-cell follicles may very well contribute to disease etiology in patients with progressive MS, and identification of the molecular mechanisms underlying the laquinimod effect on B-cell follicles could have added beneficial effects in patients. While B-cell follicles have yet to be demonstrated in patients with primary progressive MS (PPMS), ocrelizumab showed a benefit in patients with this disease phenotype,11 and a phase II clinical trial with laquinimod is ongoing (clinicaltrials.gov/ct2/show/NCT02284568).

The study by Varrin-Doyer et al. paves the way for more detailed studies determining the molecular targets of laquinimod in CNS demyelinating diseases, in particular in the context of B cells and progressive disease. The observation of a key role for B cells in the treatment effect of laquinimod brought forth by these studies is consistent with the key contributions of B cells to the etiology of MS and may open an additional alley besides anti-CD20 treatment as to how to interfere with the pathogenic effects of this lymphocyte subset in RRMS and PPMS.

STUDY FUNDING

No targeted funding reported.

DISCLOSURE

T. Forsthuber has served on the editorial boards of Clinical Immunology, Journal of Immunology, PLoS One, and Frontiers in Multiple Sclerosis and Neuroimmunology and Immunotherapy; and has received research support from the National MS Society. O. Stuve received travel funding from Teva Pharmaceuticals; is on the editorial board for JAMA Neurology, Therapeutic Advances in Neurologic Disorders, Clinical and Experimental Immunology, and MS Journal; consulted for Huron Navigant Consulting; received research support from Teva Pharmaceuticals, Opexa Therapeutics, US Department of Veterans Affairs, and Biomedical Laboratory Research and Development; has served on scientific advisory boards for Pfizer and Sanofi-Aventis; has served on the editorial boards of JAMA Neurology, Therapeutic Advances in Neurological Disorders, Clinical and Experimental Immunology, and MS Journal; and has received research support from Teva Pharmaceuticals Opexa Therapeutics and the Department of Veterans Affairs. Go to Neurology.org/nn for full disclosure forms.

Footnotes

  • Funding information and disclosures are provided at the end of the editorial. Go to Neurology.org/nn for full disclosure forms.

  • See article

  • © 2016 American Academy of Neurology

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

REFERENCES

  1. 1.↵
    1. Comi G,
    2. Jeffery D,
    3. Kappos L, et al.
    Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012;366:1000–1009.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Vollmer TL,
    2. Sorensen PS,
    3. Selmaj K, et al.
    A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol 2014;261:773–783.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Schulze-Topphoff U,
    2. Shetty A,
    3. Varrin-Doyer M, et al.
    Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One 2012;7:e33797.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Jolivel V,
    2. Luessi F,
    3. Masri J, et al.
    Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain 2013;136:1048–1066.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Yang JS,
    2. Xu LY,
    3. Xiao BG,
    4. Hedlund G,
    5. Link H
    . Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 2004;156:3–9.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Varrin-Doyer M,
    2. Pekarek KL,
    3. Spencer CM, et al.
    Laquinimod treatment of spontaneous EAE reduces Tfh, B cell aggregates, and disease progression. Neurol Neuroimmunol Neuroinflamm 2016:3:e272. doi: 10.1212/NXI.0000000000000272.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Bettelli E,
    2. Baeten D,
    3. Jager A,
    4. Sobel RA,
    5. Kuchroo VK
    . Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest 2006;116:2393–2402.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Hauser SL,
    2. Waubant E,
    3. Arnold DL, et al.
    B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676–688.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Kappos L,
    2. Li D,
    3. Calabresi PA, et al.
    Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378:1779–1787.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Toubi E,
    2. Nussbaum S,
    3. Staun-Ram E, et al.
    Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis. J Neuroimmunol 2012;251:45–54.
    OpenUrlCrossRefPubMed
  11. 11.↵
    Ocrelizumab Use in Primary Progressive Multiple Sclerosis (PPMS). Barcelona: ECTRIMS; 2015.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • STUDY FUNDING
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Info & Disclosures

Related Articles

  • No related articles found.

Topics Discussed

  • Multiple sclerosis

Alert Me

  • Alert me when eletters are published
Advertisement
Neurology - Neuroimmunology Neuroinflammation: 9 (4)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise